Alzinova AB
STO:ALZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alzinova AB
Common Stock
Alzinova AB
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alzinova AB
STO:ALZ
|
Common Stock
kr27.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
46%
|
CAGR 10-Years
38%
|
|
|
Biogaia AB
STO:BIOG B
|
Common Stock
kr20.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Common Stock
kr41.7m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Common Stock
kr28m
|
CAGR 3-Years
0%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Common Stock
kr196m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alzinova AB
Glance View
Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2015-11-25. The firm is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The firm focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
See Also
What is Alzinova AB's Common Stock?
Common Stock
27.4m
SEK
Based on the financial report for Dec 31, 2025, Alzinova AB's Common Stock amounts to 27.4m SEK.
What is Alzinova AB's Common Stock growth rate?
Common Stock CAGR 10Y
38%
Over the last year, the Common Stock growth was 17%. The average annual Common Stock growth rates for Alzinova AB have been 48% over the past three years , 46% over the past five years , and 38% over the past ten years .
